Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05719714 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05719714 · ClinicalTrials.gov record · last posted 2026-07-30

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Name: Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — clinical trial record (NCT05719714)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorNorthwestern University

Started2024-01-16

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

Protocol amendment history 2 changes detected by DataLookout

2026-07-31

Enrollment closed, study ongoing

2026-07-31

Enrollment reduced: 60 → 18 participants

Trial Details

NCT Number	NCT05719714
Lead Sponsor	Northwestern University Collaborators: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
Enrollment	18 participants
Start Date	2024-01-16
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-30